MEVLYQ

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania.

Active ingredients

The drug MEVLYQ contains one active pharmaceutical ingredient (API):

1	Eribulin mesylate UNII AV9U0660CW - ERIBULIN MESYLATE
	Eribulin is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.
	Read more about Eribulin mesylate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MEVLYQ Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX41	Eribulin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX41

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3064878
IT	Agenzia del Farmaco	051108013
LT	Valstybinė vaistų kontrolės tarnyba	1099022